Therapeutic Response of Chronic Active Hepatitis B (Cahb) to Anewimmunomodulator:AM3. Immunohematological Effects

References

• Davis GL, Hoofnagle JH. Interferon in viral hepatitis: Role in pathogenesis and treatment. Hepatology 1986; 6: 1038–1041
   PubMed Web of Science ®Google Scholar
• Ikeda T, Lever A ML, Thomas HC. Evidence for a deficiency of interferon production in patients with chronic hepatitis B virus infection acquired in adult life. Hepatology 1986; 6: 962–965
   PubMed Web of Science ®Google Scholar
• Kato Y, Nakogawa H, Kobayashi K, et al. Interferon production by peripheral lymphocytes in HBeAg-positive liver diseases. Hepatology 1982; 2: 789–790
   PubMed Web of Science ®Google Scholar
• Abb J, Zachoval R, Eisenberg J, et al. Production of interferon alpha and interferon gamma by peripheral blood leukocytes from patients with chronic hepatitis B virus infection. J Med Virol 1985; 16: 171–176
   PubMed Web of Science ®Google Scholar
• Montano L, Aranguibel F, Bofill M, Goodall AM, Janossy G, Thomas HC. An analysis of the composition of the inflammatory infiltrate in autoimmune and hepatitis B virus-induced chronic liver disease. Hepatology 1983; 3: 292–296
   PubMed Web of Science ®Google Scholar
• Yoshioka K, Kakumu S, Murakami H, Fukui K. Interleukin-2 activity in chronic active liver diseases: Response by T cells and in the autologous mixed lymphocyte reaction. Clin Exp Immunol 1984; 56: 668–676
   Web of Science ®Google Scholar
• Civeira MP, Prieto J, Anton E, Iraburu M, Morte S, Serrano M. Unbalanced immunoregulatory factors in hepatitis B virus-induced chronic active hepatitis (HBV-CAH). J Hepatol 1985; 2: S213
   Google Scholar
• Iraburu M, Civeira MP, Serrano M, Morte S, Castilla A, Prieto J. Suppressor T-cell activity in chronic hepatitis B-virus infection: Relationship with the presence of HBV-DNA in serum. J Med Virol 1989; 27: 39–43
   PubMed Web of Science ®Google Scholar
• Dienes HP, Hutteroth T, Hess G, Meuer S. Immunoelectron microscopic observations on the inflammatory infiltration and HLA antigens in hepatitis B and non-A non-B. Hepatology 1987; 7: 1317–1325
   PubMed Web of Science ®Google Scholar
• Thomas HC, Montano L, Goodall A, et al. Immunologic mechanisms in chronic hepatitis B virus infection. Hepatology 1982; 2: S116–121
   Web of Science ®Google Scholar
• Garcia Monzon C, Moreno Otero R, Pajares JM, et al. Expression of a novel activation antigen on intrahepatic CD8 T lymphocytes in viral chronic active hepatitis. Gastroenterology 1990; 98: 1029–1035
   PubMed Web of Science ®Google Scholar
• Pasquinelli C, Laure F, Romet-Lemonne JL, et al. Hepatitis B virus (HBV) DNA in mononuclear blood cells: an early, frequent and stable event which reflects the liver cell status. J Hepatol 1985; 2: S303
   Google Scholar
• Zeldis JB, Mugishima H, Steinberg H, Nir E, Gale RP. HBV inhibition of myeloid differentiation. J Clin Invest 1986; 78: 411–417
   PubMed Web of Science ®Google Scholar
• Demetris AJ, Jaffe R, Sheahan DG, et al. Recurrent hepatitis B in liver allograft recipients: differentiation between viral hepatitis B and rejection. Am J Pathol 1986; 125: 161–172
   PubMed Web of Science ®Google Scholar
• Portmann B, O'Grady J, Williams R. Disease recurrence following orthotopic liver transplantation. Transplant Proc 1986; 136–141; S4
   PubMed Web of Science ®Google Scholar
• Gouw AS, Houthoff HJ, Huitema S, Beelen JM, Gips CH, Poppema S. Expression of major histocompatibility complex antigens and replacement of donor cells by recipient ones in human liver grafts. Transplantation 1987; 43: 291–296
   PubMed Web of Science ®Google Scholar
• Villarrubia VG, Lopez Elorza F, Sada G, Valladolid J, Herrerlas JM. AM3: a second signal BRM. Its use in bone-marrow depression and chronic viral infections. EOS J Immunol Immunopharmacol 1990; 10: 227–228
   Google Scholar
• Villarrubia VG, Herrerias JM, Valladolid JM, Sada G, Vilchez JG, Yelorza FL. Inflammatory response, haematopoiesis and chronic viral hepatitis. Gastroenterol Hepatol (Spain) 1990; 13: 264–265
   Google Scholar
• Dooley JS, Davis GL, Peters M, Waggoner JG, Goodman Z, Hoofnagle JM. Pilot study of recombinant human alpha-interferon for chronic type B hepatitis. Gastroenterology 1986; 90: 150–157
   PubMed Web of Science ®Google Scholar
• Alexander G JM, Brahm J, Fagan EA, et al. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. Lancet 1987; ii: 66–68
   Google Scholar
• Castilla A, Civeira MP, Jauregui JI, et al. Tratamiento de la hepatitis cronica B con interferon alfa linfoblastoide. Med Clin 1989; 93: 601–603
   PubMed Web of Science ®Google Scholar
• Villarrubia VG, Sada G, Luini W, Sozzani SY, Spreafico F. Restauraciòn por AM3 de la actividad citotoxica antitumoral de celulas NK y macrófagos en animates inmunocomprometidos. Oncologfa 1987; 10: 283–291
   Google Scholar
• Canˆavate ML, Ponton J, Amurrio C, et al. Efecto de un nuevo inmunomodulador sobre la funcionalidad de macrofagos de ratdn. Rev Clin Esp 1984; 3: 159–162
   Google Scholar
• Barasoain I, Rejas MT, Aramburu J. Inmunoferon (AM3) aumenta la production de IL-1 y restaura la capacidad fagocítica de macrófagos en ratones inmunodeprimidos. XII Cong Nal de Microbiol 1989, Abstr 37
   Google Scholar
• Moya P, Baixeras E, Barasoain I, et al. Inmunoferon (AM3) enhances the activities of early-type interferon inducers and natural-killer cells. Immunopharmacol Immunotoxicol 1987; 9: 243–256
   PubMed Web of Science ®Google Scholar
• Rojo JM, Rejas MT, Ojeda G, Portoles P, Barasoain I. Enhacement of lymphocyte proliferation, interleukin-2 production and NK activity by Immunoferon (AM3), a fungal immunomodulator: Variations in normal and immuno-suppressed mice. Int J Immunopharmacol 1986; 8: 593–597
   PubMed Web of Science ®Google Scholar
• Camacho F, Elorza FL, Ortega M, Elorza MA, Sada G, Villarrubia VG. AM3 (a new biological response modifier) in the treatment of recurrent aphtous stomatitis (RAS). Clinical evaluation and its relation with CD16/NK blood cell changes. Rev Clin Esp 1991; 188: 403–408
   PubMed Web of Science ®Google Scholar
• Milla A, Sanchiz F, Sada G, Villarrubia VG. Bone-marrow recuperation by AM3 in breast cancer patients submitted to aggressive adjuvant treatment. A preliminary report. Anticancer Research 1986; 6: 865–868
   PubMed Web of Science ®Google Scholar
• Levy De, Rosetti I, Dosoretz B, Marquez P, Sada G, Villarrubia VG. Recuperatíon mediante AM3, un modificador de la respuesta biológica (MRB) oral, de la depresión iatrogénica de leucocitos periféricos y plaquetas en pacientes con cáncer de mama sometidas a radioterapia y quimioterapia adyuvante. Cancerología (México) 1989; 35: 725–733
   Google Scholar
• Villarrubia VG, Sada G, Marquez P, Dosoretz B, Rosettii Levy DE. Spontaneous and AM3-induced bone-marrow recovery after radio-chemotherapy arrest seem to depend on levels of peripheral blood mononuclear cells. Int J Immunother 1988; IV(3)177–185
   Google Scholar
• De La Garza JG, Ramirez MT, Ramirez M, Alam N. Effects of AM3, a new biological response modifier (BRM), on granulocyte reconstitution in patients receiving chemotherapy for breast cancer. ASCO Proc. 1989; 8: A688
   Google Scholar
• Alberola V, Lluch A, Carbonell F, Garcia-Conde J, Sada G, Villarrubia VG. Early recuperation of tha PBL normal levels in patients with non-operable NSCLC submited to chemotherapy. Proc 5th NIC-EORTC Symp on new drugs in cancer therapy. Amsterdam 1986; 6: 20
   Google Scholar
• Garcia De Villaescusa R, Otero Martinez L, Sada G, Villarrubia VG. Inflammatory and haematologic responses in breast cancer patients under adjuvant radiotherapy (A-RT). Effects of treatment with AM3. Anticancer Research 1990; 10(5 B)1429, Abstr 262
   Google Scholar
• Villarrubia VG, Sada G. Immunity, immunocompromise and infection: the role of Immunoferon (AM3). Fondo edit. Lab Andrómaco, Madrid 1989; 34–40
   Google Scholar
• Herrerias JM, Valladolid JM, Villarrubia VG, et al. Antiviral and immunohematologic effects of AM3 in patients with chronic active hepatitis B. A pilot study in 13 patients. Curr Ther Res 1991; 49: 556–574
   Web of Science ®Google Scholar
• Villarrubia VG, Sada G, Herrerias JM, Valladolid JM, Vilchez JG, Elorza FL. AM3 (a new oral BRM) in the treatment of chronic active type B hepatitis (CAHB). Preventing hepatocarcinoma ?. Anticancer Research 1990; 10(5B)1427, Abstr 257
   Google Scholar
• Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin. Lab Invest 1968; 21(S97)77–89
   Google Scholar
• Lanier LL, Le AM, Phillips JH, Warner NL, Babcock GF. Subpopulations of human natural killer cells defined by expression of Leu-7 (HNK-1) and Leu 11 (NK-15) antigens. J Immunol 1983; 131: 1789–1796
   PubMed Web of Science ®Google Scholar
• Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990; 323: 295–301
   PubMed Web of Science ®Google Scholar
• Carrenˆo V, Porres JC, Mora I, et al. Prolonged (6 months) treatment of chronic hepatitis B virus infection with recombinant leukocyte A interferon. Liver 1987; 7: 325–332
   PubMedGoogle Scholar
• Perrillo RP, Regenstein FG, Peters MG, et al. Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial. Ann Intern Med 1988; 109: 95–100
   PubMed Web of Science ®Google Scholar
• Goldstein D, Laszlo J, Rudnick S. Interferon therapy in cancer. Principles of cancer biotherapy. RK Oldham edit. Raven Press, Ltd., New York 1987; 247–272
   Google Scholar
• Lam KC, Lai CL, Ng RP, et al. Deleterious effect of prednisone in HBsAg-positive chronic active hepatitis. N Engl J Med 1981; 304: 380–386
   PubMed Web of Science ®Google Scholar
• Caruso C, Canoore G, Modica MA. Nonresponse to hepatitis B vaccine. N Engl J Med 1990; 322: 550–551
   PubMed Web of Science ®Google Scholar
• Villarrubia VG. Aproximación terapeútica con modificadores de la respuesta biológica: Consideraciones al tratamiento con AM3. Symp Immunol y Dermatol. Jarpy edic, Sevilla (Spain) 1986; 49–58
   Google Scholar
• Scadden DT, Zon LI, Groopman JE. Pathophysiology and management of HIV-associated hematologic disorders. Blood 1989; 74: 1455–1463
   PubMed Web of Science ®Google Scholar
• Zeldis JB, Boender PJ, Heelings JA, Steinberg H. Inhibition of human hemopoiesis by Non-A Non-B hepatitis virus. J Med Virol 1989; 27: 34–38
   PubMed Web of Science ®Google Scholar
• Heard HK, O'Connor K, Strayer DS. Molecular analysis of immunosuppression induced by virus replication in lymphocytes. J Immunol 1990; 144: 3992–3999
   PubMed Web of Science ®Google Scholar